Today, the Indian international pharmaceutical company Cipla announced
that they received approval from the United States Food and Drug
Administration (USFDA) for its Abbreviated New Drug Application (ANDA)
for Icatibant Injectable 30mg/3mL. Cipla's Icatibant Injectable
Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire's
Firazyr®. The drug has been approved for the treatment of a rare
genetic disorder, […]
The post Cipla's Icatibant Gets USFDA Approval To Treat A Rare Genetic
Disorder appeared first on Rasayanika .
https://www.rasayanika.com/2020/07/15/ciplas-icatibant-gets-usfda-approval-to-treat-a-rare-genetic-disorder/
News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment